论文部分内容阅读
目的观察曲美布汀治疗功能性消化不良(FD)的临床疗效及安全性。方法对我院收治的60例功能性消化不良患者随机分为治疗组和对照组,治疗组用曲美布汀100 mg,3次/d,口服;对照组用多潘立酮10 mg,3次/d,口服;所有患者疗程均为4周,观察两组治疗效果。结果治疗组有效率90%,明显高于对照组73.3%(P<0.05),疗程结束时FD患者早饱、上腹胀痛、嗳气、食欲不振等症状治疗组明显改善,疗效优于对照组。治疗过程中两组均未发现明显的不良反应。结论曲美布汀能明显缓解FD患者的症状,疗效优于多潘立酮,不良反应轻微,是治疗FD安全、有效的新一代胃肠动力药物。
Objective To observe the clinical efficacy and safety of trimebutine in the treatment of functional dyspepsia (FD). Methods Sixty patients with functional dyspepsia admitted to our hospital were randomly divided into treatment group and control group. The patients in treatment group were treated with Trimebutine 100 mg three times a day orally. The control group was treated with domperidone 10 mg three times daily , Oral; All patients were treated for 4 weeks, the two groups observed the effect of treatment. Results The effective rate of the treatment group was 90%, which was significantly higher than that of the control group (73.3%) (P <0.05). At the end of the treatment period, the symptoms of premature ejaculation, abdominal pain, belching and loss of appetite in FD patients were significantly improved . No significant adverse reactions were found in both groups during the course of treatment. Conclusion Trimebutine can obviously relieve the symptoms of FD patients. The curative effect is better than that of domperidone, with mild side effects. It is a safe and effective new generation of gastrointestinal motility drug for the treatment of FD.